Jun 24, 2025
Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASH
Apr 10, 2025
Rivus Pharmaceuticals Expands Leadership Team and Establishes New San Francisco Bay Area Office Ahead of Phase 2 Read-Out in MASH
Mar 12, 2025
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology
Jan 08, 2025
Rivus Pharmaceuticals to Present Corporate Update at 2025 J.P. Morgan Healthcare Conference
Sep 30, 2024
Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related Heart Failure
Sep 23, 2024
Rivus Pharmaceuticals to Present New Data from Phase 2a HuMAIN Trial of HU6 for the Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction at Heart Failure Society of America Annual Scientific Meeting 2024
Sep 11, 2024
Rivus Pharmaceuticals Strengthens Executive Team and Board with Appointments of Tom O'Neil as Chief Financial Officer and Erin Lavelle as Director
Aug 13, 2024
Rivus Pharmaceuticals' Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure
Jun 26, 2024
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial Rationale and Design in European Journal of Heart Failure
Jan 05, 2024
Rivus Pharmaceuticals Announces Completion of Enrollment in Phase 2a HuMAIN Trial of HU6